Longitudinal analysis of abnormal domains comprising mild cognitive impairment (MCI) during aging
Introduction
Identification of individuals at risk for dementia in order to begin early therapeutic interventions is vitally important, because resulting cognitive and neurobehavioral improvements should lessen distress for patients, families and caregivers as well as minimizing risk of accidents, prolonging personal autonomy, possibly preventing onset and even halting the dementia process and formulating backup plans for future care, if necessary [1]. For these reasons, increasing attention is now being devoted to the interphases between normal aging and dementia, characterized by cognitive impairments that are insufficient to meet criteria for dementia [2].
Beginning in the early 1960s, these interphase cognitive impairments were labeled with various tags, the popularity of which has fluctuated from time to time, often influenced by support from different health organizations. Nosological terms have included “benign senescent forgetfulness” through the 1960s and 1970s [3], “age-associated memory impairments” (AAMI) in the 1980s recommended by the National Institute of Mental Health [4], and recently “age-associated cognitive decline” (AACD) recommended by the World Health Organization (WHO) [5], “cognitive impairment no dementia” (CIND) recommended by the Canadian Study of Health and Aging [6] and “mild cognitive impairment” (MCI) now recommended by the American Academy of Neurology (AAN) [7]. “Vascular cognitive impairment” (VCI) has recently been suggested to depict cognitive impairment attributable to impending or actual vascular dementia (VaD) [8], [9]. The prevalence, incidence and rates of conversion to dementia among these separately labeled transitional stages have varied widely due to different identification criteria, even when applied to populations with comparable demographics [1]. MCI, the term to be used here, is now the most frequently endorsed for describing transitional stages between normal aging and incipient dementia.
A number of studies have documented increased risk of dementia of Alzheimer's type (DAT) among MCI subjects [10], [11], [12]. However, inability to distinguish MCI that progress to dementia from those who do not still hinders prevention and early treatment of dementia. According to present criteria, if MCI subjects are treated unselectively in the hope of delaying or preventing dementia, potential risks result, which should be weighed against any benefits among healthy but frail elderly individuals treated with cholinesterase inhibitors, or vaccines, which may have adverse side effects [13], [14], [15], [16]. A possible solution for this dilemma is to analyze the cognitive impairment domains of MCI based on the hypothesis that particular domains of cognitive impairments may act as signal flags for those who will progress to dementia. There is little disagreement that memory dysfunction is a primary predictor for DAT [17], [18]. Petersen et al. [12] have suggested that in MCI general intellectual functioning should be preserved with memory being solely affected. Other investigators disagree and consider that cognitive domains besides memory may also become impaired, such as language [16], [19], orientation [20], [21], attention, concentration [22], [23] and praxis [16], [20]. To clarify such questions and confounds, further investigations, particularly longitudinal observations, should be helpful.
Section snippets
Subjects
Subjects for this research comprise volunteers enrolled in longitudinal studies of aging and dementia inaugurated in 1983 and approved annually by Institutional Review Boards of Baylor College of Medicine. These volunteers are all dwellers in and around Houston metropolitan areas. Many volunteers were relatives, caregivers and friends of our patients with stroke, VaD and DAT and so many had risk factors for stroke. This bias accounts for the high incidence of VaD developing in this population
Results
During 3.72±2.94 years of follow-up, 73 out of 291 cognitively normative subjects developed MCI and completed one or more visits after MCI identification. After an additional 3.88±3.01 years of MCI follow-up, the original 73 MCI subjects became differentiated into three groups: 35 (47.9%) developed DAT, 15 (20.5%) developed VaD and 23 (31.5%) MCI persisted at the time follow-up was closed for data analysis or dropped out (by death, moving out of the area or refusal to continue). Demographic
Discussion
This longitudinal study confirms that MCI subjects are at high risk for dementia, particularly DAT. Individuals with MCI, however, may have one or more cognitive domains impaired other than memory. Impairments of special cognitive domains and deterioration rates predict DAT. Multi-domain MCI is more likely to progress to DAT than single-domain MCI. These conclusions are partly supported by reports of others [1], [5], [17], [18], [20], [21], [22].
Previous investigations have reported that
Acknowledgements
This study was supported by the Department of Veterans Affairs Central Office in Washington, DC, Meyer Research Foundation of Baylor College of Medicine. Felicia Cruise, Yansheng Li, Melissa Phinney and Peter Hinh helped in collecting clinical data and Irma Muniz and Cora Bess Meyer provided administrative assistance.
References (62)
- et al.
Mild cognitive impairment: conceptual basis and current nosological status
Lancet
(2000) - et al.
Prevalence and severity of cognitive impairment with and without dementia in an elderly population
Lancet
(1997) - et al.
Volumes of medial temporal lobe structures in patients with Alzheimer's disease and mild cognitive impairment (and in healthy controls)
Biol. Psychiatry
(1998) - et al.
Retrieval and encoding of episodic memory in normal aging and patients with mild cognitive impairment
Brain Res.
(2002) - et al.
The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: relationship to episodic and semantic memory impairment
Neuropsychologia
(2000) - et al.
“Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician
J. Psychiatr. Res.
(1975) Apolipoprotein E and Alzheimer's disease
Curr. Opin. Neurobiol.
(1994)- et al.
The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: relationship to episodic and semantic memory impairment
Neuropsychologia
(2000) - et al.
Choline acetyltransferase activity and cognitive domain scores of Alzheimer's patients
Neurobiol. Aging
(2000) Cognitive functions of the basal forebrain cholinergic system in monkeys: memory or attention?
Behav. Brain Res.
(1996)